Clinical Trials for Ovarian Cancer

A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Single-arm study for adults with recurrent platinum-resistant epithelial ovarian cancer (1–3 prior lines; ECOG 0–2), including prior frontline PARP inhibitor but no prior CDK4/6 inhibitor; dose-expansion limited to high-grade serous disease with biopsy-accessible tumors. Patients receive continuous olaparib (PARP inhibitor) plus abemaciclib (CDK4/6 inhibitor causing G1 arrest) to evaluate safety and preliminary activity of this combination based on proposed synthetic lethality and replication-stress synergy.

ClinicalTrials.gov ID: NCT04633239

Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and symptomatic malignant ascites/pleural effusion (ECOG 0–1; prior therapies and platinum sensitivity unrestricted) are randomized to pegcetacoplan (C3 complement inhibitor) plus pembrolizumab with or without bevacizumab versus bevacizumab alone. Aims include reducing effusion burden and assessing antitumor activity; key exclusions include active autoimmune disease requiring treatment, recent immunosuppression, recent checkpoint inhibitor, uncontrolled CV disease, and active HBV/HCV viremia.

ClinicalTrials.gov ID: NCT04919629

A Phase 1b Study of BCL-XL Degrader DT2216 in Combination With Weekly Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable platinum-resistant recurrent or refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer and up to four prior systemic therapy lines receive weekly paclitaxel plus DT2216, an investigational PROTAC that recruits VHL to degrade the anti-apoptotic protein BCL-XL. Prior weekly paclitaxel for recurrent disease or BCL-XL inhibition is not allowed.

ClinicalTrials.gov ID: NCT06964009

A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced solid tumors that have progressed after standard therapy or lack a standard treatment option receive a single intravenous infusion of IDOV-Immune. This engineered oncolytic vaccinia virus is designed to replicate preferentially in tumor cells, destroy them, and stimulate antitumor immunity.

ClinicalTrials.gov ID: NCT06910657

A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, locally advanced unresectable or metastatic FAP-positive solid tumors receive intravenous LY4337713, an investigational lutetium-177 radioligand that targets fibroblast activation protein on cancer-associated fibroblasts to deliver radiation to tumors. Eligible cancers include pancreatic, breast, ovarian, gastric, colorectal, esophageal, and cholangiocarcinoma.

ClinicalTrials.gov ID: NCT07213791

A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination With Immune Checkpoint Inhibition in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with refractory, locally advanced or metastatic NSCLC, triple-negative breast cancer, head and neck squamous cell carcinoma, esophageal or gastric/GEJ cancer, or cervical, endometrial, or ovarian cancer (ECOG 0–1) receive NRM-823 alone or with an immune checkpoint inhibitor. NRM-823 is an investigational T-cell engager intended to bring T cells into contact with tumor cells; its tumor-binding target has not been publicly confirmed.

ClinicalTrials.gov ID: NCT07182149

First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, advanced CA19-9–expressing solid tumors and no standard treatment option likely to benefit them receive BNT329, an investigational CA19-9–directed antibody–drug conjugate carrying a topoisomerase I inhibitor. Cohorts test different dosing schedules, one with a CA19-9–targeting antibody given before BNT329; a previously treated pancreatic cancer cohort compares two BNT329 doses.

ClinicalTrials.gov ID: NCT07186842

A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with ECOG ≤1 and advanced metastatic/unresectable HER2-expressing or HER2-amplified solid tumors lacking effective standard options, with an expansion cohort limited to platinum-resistant high-grade serous ovarian carcinoma (progression <6 months after last platinum) with HER2 IHC 1+ and a biopsy-accessible lesion. Patients receive trastuzumab deruxtecan (HER2-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor payload) IV every 21 days plus oral olaparib (PARP inhibitor) twice daily on intermittent or continuous schedules.

ClinicalTrials.gov ID: NCT04585958

A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination With Bevacizumab in Adult Subjects With Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or unresectable platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer who have received no more than five prior lines of therapy receive intravenous ABBV-901, an investigational folate receptor alpha–directed antibody–drug conjugate, alone or with bevacizumab.

ClinicalTrials.gov ID: NCT07278336

A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, as Monotherapy in Participants With Platinum-Resistant Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with platinum-resistant high-grade serous ovarian, primary peritoneal, or fallopian tube cancer, excluding primary platinum-refractory disease, receive MEN2501 monotherapy. MEN2501 is an investigational oral KIF18A inhibitor intended to disrupt chromosome movement during cell division.

ClinicalTrials.gov ID: NCT07226427